US Patent 7232797 Erythropoietin dosing regimen for treating anemia
Patent 7232797 was granted and assigned to Ortho-McNeil Pharmaceutical on June, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+256 characters)
Article
Patent abstract
The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing.
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07232797 Erythropoietin dosing regimen for treating anemia US Patent 7232797 Erythropoietin dosing regimen for treating anemia
Infobox
Patent Number
0723279700
Patent Number
723279700
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072327970
Date of Patent
June 19, 2007
0Patent Application Number
103043820
Date Filed
November 26, 2002
0Official Website
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072327970
Date of Patent
June 19, 2007
0Patent Application Number
103043820
Date Filed
November 26, 2002
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 21 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07232797 Erythropoietin dosing regimen for treating anemia
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07232797
Date of patent
June 19, 2007
Patent application number
10304382
Date Filed
November 26, 2002
Patent primary examiner
Find more entities like US Patent 7232797 Erythropoietin dosing regimen for treating anemia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.